Gilead Sciences Inc at Nasdaq Investor Conference Transcript
All right. Perfect. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts at Morgan Stanley. Really pleased to have Dan O'Day, the Chairman and CEO at Gilead with us.
Just a reminder, personal analyst holding disclosures are available on morganstanley.com/researchdisclosures. And with that fun out of the way, Dan, thanks for being here. I thought maybe a good place to start off is we're sort of -- I guess you're 3 years into your tenure almost?
' -
Yes. Almost 4.
Questions & Answers
Almost 4, yes, that's right. And obviously, part of the -- when you came in, right, was a transformation of the company, right? You put a lot of capital to work on external assets. So where do you think you are in the transition of the company, sort
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
